IFNGR1 and neoplasm: While our data shows that loss of IFNγR/JAK/STAT signaling generally sensitizes tumor cells to CAR-T therapy in vivo, it also shows that perturbations that lead to amplified or altered IFNγR signaling can, as suggested in previous studies, sensitize tumors to a non-specific death induced by activated T cells28.